DGAP-News: iovera Introduced in Europe as the World's First Toxin-Free Treatment for Dynamic Facial Lines
(firmenpresse) - myoscience
04.04.2013 06:00
---------------------------------------------------------------------------
MONACO, 2013-04-04 06:00 CEST (GLOBE NEWSWIRE) --
myoscience, inc. presents European launch of its ground breaking toxin-free
treatment, iovera?, at The Anti-Aging Medicine World Congress (AMWC) in Monaco.
iovera? is a new tool for aesthetic physicians for the treatment of dynamic
facial lines. iovera? immediately reduces the appearance of forehead lines
using only the body's natural response to cold.
iovera? targets facial lines precisely using Focused Cold Therapy(TM), an
advanced technology that works immediately and temporarily relaxes facial
muscles that cause wrinkles without leaving any toxins or chemicals behind in
the body. Many people who want to treat their dynamic facial lines but are
uncomfortable with previously available treatments now have a new option with
iovera?.
Clint Carnell, CEO of myoscience, is excited to see iovera? come alive in the
hands of physicians in Europe. 'We developed iovera? in partnership with some
of the world's leading physicians. There is powerful consumer demand for a
wrinkle solution that has no toxins and no wait for results, so there's no
worry for patients about getting back to their regular lifestyle.'
Dr. Jonathan Sykes, Director of Facial Plastic Surgery, UC Davis Medical
Center, California, who will present about iovera? at AMWC says, 'Recent
in-clinic market research of nearly 4,000 patients demonstrates that the offer
of an effective toxin-free, minimally invasive option for dynamic forehead
lines is a very attractive proposition. iovera? not only appeals to consumers
new to aesthetic procedures, but also to existing patients.' He adds, 'iovera?
is an exciting breakthrough in medical aesthetics because it will create new
opportunities by opening clinic doors to a previously unseen consumer group
seeking an effective, quick, toxin-free treatment option.'
iovera? will be available first to physicians in the UK, Germany, the
Netherlands, Belgium and France, with planned expansion into the rest of the EU
throughout 2013.
About myoscience
Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy(TM),
the standard of care for the treatment of peripheral nerve conditions. Focused
Cold Therapy is currently approved in Europe and Canada for temporary wrinkle
reduction, temporary pain reduction and treatment of dermatologic conditions.
The myoscience technology has also been cleared in the United States for use in
pain management and general surgical use. For more information, please visit
www.myoscience.com.
The myoscience logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13581
CONTACT: Alexandra Mack650-421-0609amack(at)myoscience.com
News Source: NASDAQ OMX
04.04.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: myoscienceUnited States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9902131674
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.04.2013 - 06:00 Uhr
Sprache: Deutsch
News-ID 245793
Anzahl Zeichen: 4412
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 290 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: iovera Introduced in Europe as the World's First Toxin-Free Treatment for Dynamic Facial Lines"
steht unter der journalistisch-redaktionellen Verantwortung von
myoscience (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
